Phaseline

Companies › Indaptus Therapeutics

Indaptus Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Decoy20
Multiple Toll-like receptor (TLR) agonist
–Phase 1Solid Tumor, AdultJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05651022Decoy20Phase 1Solid Tumor, AdultOncologyJun 2027

From the company's SEC filings

Cash and short-term investments of $12m on 2026-06-30; operating cash outflow about $18m a year; runway about 8 months at that burn, to Feb 2027

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.